TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11334210

Group type: EXPERIMENTAL
Intervention: Leucofiltration (LF)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control therapy (CT)
Number of subjects: 24
Study: 9675433

Group type: EXPERIMENTAL
Intervention: Tetracaine-lidocaine-phenylephrine (TetraLidoPhen)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Lidocaine infiltration
Number of subjects: 90
Study: 8120217

Group type: EXPERIMENTAL
Intervention: Clearfil F2/etching
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Panavia EX/sandblasting
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Microfill Pontic C/silicate-coating
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: General dental practices
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Maxillary PRBBs
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Mandibular PRBBs
Number of subjects: 201
Study: 2172351

Group type: EXPERIMENTAL
Intervention: Histamine (intradermal injection, 50 microliters, concentrations ranging from 3.3 x 10(‐4) to 3.3 x 10(‐9) mol/L)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Leukotrienes C4, D4, and E4 (intradermal injection, 50 microliters, concentrations ranging from 2 x 10(‐4) to 2 x 10(‐9) mol/L)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Histamine (intradermal injection, 50 microliters)
Number of subjects: 20
Study: 373088

Group type: EXPERIMENTAL
Intervention: 50 mg levamisole tablets, one tablet t.i.d. for 3 months, then one tablet t.i.d. on 2 consecutive days every week for the next 3 months
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 50 mg levamisole tablets
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 33
Study: 30288741

Group type: EXPERIMENTAL
Intervention: Oesophageal compression by 30 N paratracheal force (paratracheal group)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Oesophageal compression by 30 N cricoid force (cricoid group)
Number of subjects: 90

Group type: COMPARATOR
Intervention: No oesophageal compression (control group)
Number of subjects: 90
Study: 28345814

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg once daily plus exenatide 2 mg once weekly
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 26041602

Group type: EXPERIMENTAL
Intervention: Candesartan 8 mg + Hydrochlorothiazide 6.25 mg (combination regimen)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Candesartan 12 mg (maximum dose regimen)
Number of subjects: 206
Study: 25608547

Group type: EXPERIMENTAL
Intervention: Community-based comprehensive fall prevention program (balance exercises, elastic resistance exercises, prevention education), provided five times a week for 8 weeks, each session lasting 90 minutes.
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided).
Number of subjects: 57
Study: 21618678

Group type: EXPERIMENTAL
Intervention: Iodixanol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ioxaglate
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Anticoagulants (enoxaparin, unfractionated heparin, fondaparinux, bivalirudin)
Number of subjects: 12
Study: 19731994

Group type: EXPERIMENTAL
Intervention: Diclofenac plus B vitamins (50 mg diclofenac + 50 mg thiamine + 50 mg pyridoxine + 1 mg cyanocobalamin)
Number of subjects: 372

Group type: COMPARATOR
Intervention: Diclofenac monotherapy (50 mg diclofenac)
Number of subjects: 372
Study: 17963111

Group type: EXPERIMENTAL
Intervention: 4-methylpyrazole (4-MP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15480514

Group type: EXPERIMENTAL
Intervention: MRI examination after radiotherapy
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: MRI examination
Number of subjects: 7
Study: 11443205

Group type: EXPERIMENTAL
Intervention: Pegvisomant (1 mg/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline (0.5 mL)
Number of subjects: 12
Study: 9522024

Group type: COMPARATOR
Intervention: Chloral hydrate (CH) 500 mg as drinking solution
Number of subjects: 18

Group type: COMPARATOR
Intervention: Chloraldurat rot (CR) one capsule
Number of subjects: 18

Group type: COMPARATOR
Intervention: Chloraldurat blau (CB) one capsule
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Reference drinking solution (150 ml)
Number of subjects: 18
Study: 8019117

Group type: EXPERIMENTAL
Intervention: pH adjusted 0.75% bupivacaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: 50:50 mixture of 1% lignocaine and 0.5% bupivacaine with hyaluronidase
Number of subjects: 0
Study: 3383574

Group type: EXPERIMENTAL
Intervention: NET:CHOL (norethisterone-cholesterol eutectic mixture)
Number of subjects: 5

Group type: COMPARATOR
Intervention: NET:LAC (control formulation)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Dianor (commercial tablet)
Number of subjects: 5
Study: 31340755

Group type: EXPERIMENTAL
Intervention: Gadoxetic acid-enhanced MRI
Number of subjects: 128

Group type: COMPARATOR
Intervention: Multidetector CT (MDCT)
Number of subjects: 128
Study: 28974344

Group type: EXPERIMENTAL
Intervention: Lifesaver
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Face-to-face (F2F) training
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Combined group (Lifesaver + F2F)
Number of subjects: 81

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 81
Study: 26310670

Group type: EXPERIMENTAL
Intervention: AL‐8309B 1.0%
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: AL‐8309B 1.75%
Number of subjects: 768

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 768
Study: 23850610

Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) administration of LIPO-4 vaccine (0.5 ml, 500 μg of each lipopeptide)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Intradermal (ID) administration of LIPO-4 vaccine (0.1 ml, 100 μg of each lipopeptide)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Intradermal (ID) administration of LIPO-4 vaccine
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) administration of LIPO-4 vaccine
Number of subjects: 68
Study: 21498394

Group type: EXPERIMENTAL
Intervention: Capecitabine
Number of subjects: 568

Group type: EXPERIMENTAL
Intervention: Haplotypes
Number of subjects: 568
Study: 19884541

Group type: EXPERIMENTAL
Intervention: Intrathecal methotrexate
Number of subjects: 171

Group type: COMPARATOR
Intervention: Triple intrathecal therapy (methotrexate with cytarabine and hydrocortisone)
Number of subjects: 171
Study: 17325684

Group type: EXPERIMENTAL
Intervention: Phone approach
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Clinic approach
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 96
Study: 14702493

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 0.3%/dexamethasone 0.1% otic suspension, 4 drops twice daily for 7 days
Number of subjects: 599

Group type: COMPARATOR
Intervention: Ofloxacin 0.3% otic solution, 5 drops twice daily for 10 days
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin/dexamethasone
Number of subjects: 599

Group type: COMPARATOR
Intervention: Ofloxacin
Number of subjects: 599
Study: 11381675

Group type: EXPERIMENTAL
Intervention: E5880 (300 micrograms or 1200 micrograms twice daily) administered intravenously for 14 days
Number of subjects: 71
Study: 9268994

Group type: EXPERIMENTAL
Intervention: Pars plana vitrectomy with identified risk factors
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (age- and sex-matched subjects)
Number of subjects: 42
Study: 8094828

Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (IVMP) 500 mg daily for 5 days
Number of subjects: 242

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (IVMP)
Number of subjects: 242
Study: 3531936

Group type: EXPERIMENTAL
Intervention: 1 or 2 mg pure porcine relaxin
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo (distilled water)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: 2 mg pure porcine relaxin
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Intracervical application of relaxin
Number of subjects: 71
Study: 31131671

Group type: EXPERIMENTAL
Intervention: Arterial Spin Labeling (ASL) imaging at 48 hours, 7 days, and 30 days after ICH onset
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Baseline systolic blood pressure (SBP) measurements
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Perilesional rCBF measurement
Number of subjects: 20
Study: 30093093

Group type: EXPERIMENTAL
Intervention: 3D laparoscopic tasks with eye exercises
Number of subjects: 24

Group type: COMPARATOR
Intervention: 3D laparoscopic tasks without eye exercises
Number of subjects: 24

Group type: COMPARATOR
Intervention: 2D laparoscopic tasks
Number of subjects: 24
Study: 27793204

Group type: EXPERIMENTAL
Intervention: 1 g of intravenously administered ferric carboxymaltose
Number of subjects: 0

Group type: COMPARATOR
Intervention: 10 g of iron fumarate supplements at one to two daily doses of 100 mg each
Number of subjects: 0
Study: 24690309

Group type: EXPERIMENTAL
Intervention: Diary self-monitoring of blood glucose (SMBG) records
Number of subjects: 95

Group type: COMPARATOR
Intervention: Meter self-monitoring of blood glucose (SMBG) records
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Overall monitoring process
Number of subjects: 95
Study: 21955037

Group type: EXPERIMENTAL
Intervention: Trial-based thought record (TBTR)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional cognitive therapy (CCT)
Number of subjects: 36
Study: 20952764

Group type: EXPERIMENTAL
Intervention: Naltrexone (NTX)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acamprosate (ACAMP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17346288

Group type: EXPERIMENTAL
Intervention: EIMD (exercise-induced muscle damage) group jumped 100 times from a 35 cm bench
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no muscle-damaging exercise)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: EIMD group
Number of subjects: 30
Study: 15766302

Group type: EXPERIMENTAL
Intervention: Once-weekly oral morphine
Number of subjects: 23

Group type: COMPARATOR
Intervention: Lorazepam
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 11982838

Group type: EXPERIMENTAL
Intervention: 1.5% lidocaine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Physiological saline
Number of subjects: 15
Study: 10218756

Group type: EXPERIMENTAL
Intervention: Trace elements (zinc sulfate and selenium sulfide)
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: Vitamins (beta carotene, ascorbic acid, and vitamin E)
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: Trace elements (zinc and selenium sulfide)
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: Trace elements and vitamins
Number of subjects: 725

Group type: COMPARATOR
Intervention: All groups (including control)
Number of subjects: 725
Study: 7599570

Group type: EXPERIMENTAL
Intervention: Granisetron
Number of subjects: 30

Group type: COMPARATOR
Intervention: Comparator (metoclopramide, dexamethasone phosphate, and lorazepam)
Number of subjects: 30
Study: 2096775

Group type: EXPERIMENTAL
Intervention: Thiotepa instillations in the bladder
Number of subjects: 155

Group type: COMPARATOR
Intervention: Adriamycin instillations in the bladder
Number of subjects: 155

Group type: COMPARATOR
Intervention: Cisplatin instillations in the bladder
Number of subjects: 155
Study: 630810

Group type: EXPERIMENTAL
Intervention: Extracellular volume expansion (ECVE) during water diuresis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water diuresis alone
Number of subjects: 0
Study: 31182147

Group type: EXPERIMENTAL
Intervention: Self-regulation-based e- and m-health intervention 'MyPlan 2.0' with action planning, coping planning, and self-monitoring techniques.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified what intervention they receive).
Number of subjects: 0
Study: 28822563

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (placebo controlled trial)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 147
Study: 25736397

Group type: EXPERIMENTAL
Intervention: udenafil 50mg
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: udenafil 75mg
Number of subjects: 346

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 346
Study: 22842285

Group type: EXPERIMENTAL
Intervention: Biphasic Rectilinear (BR) waveform
Number of subjects: 199

Group type: COMPARATOR
Intervention: Biphasic Truncated Exponential (BTE) waveform
Number of subjects: 199
Study: 21372264

Group type: EXPERIMENTAL
Intervention: Hypertensive T2DM patients
Number of subjects: 3738

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure (BP)
Number of subjects: 3738

Group type: EXPERIMENTAL
Intervention: Independent factors associated with albuminuria
Number of subjects: 3738

Group type: EXPERIMENTAL
Intervention: Independent risk factors for renal insufficiency (RI)
Number of subjects: 3738
Study: 19926048

Group type: EXPERIMENTAL
Intervention: 0.50 mg/kg enoxaparin
Number of subjects: 3528

Group type: EXPERIMENTAL
Intervention: 0.75 mg/kg enoxaparin
Number of subjects: 3528

Group type: COMPARATOR
Intervention: UFH (unfractionated heparin)
Number of subjects: 3528

Group type: EXPERIMENTAL
Intervention: Nonfatal myocardial infarction and/or urgent target vessel revascularization
Number of subjects: 3528

Group type: EXPERIMENTAL
Intervention: Major bleeding within 48 h
Number of subjects: 3528
Study: 16427543

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IP) with 10 minutes of portal triad clamping and 10 minutes of reperfusion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group without ischemic preconditioning
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IP)
Number of subjects: 60
Study: 14657039

Group type: EXPERIMENTAL
Intervention: Protein supplement (8 g carbohydrate, 10 g protein, 3 g fat)
Number of subjects: 387

Group type: COMPARATOR
Intervention: Placebo (0 g carbohydrate, 0 g protein, 0 g fat)
Number of subjects: 387

Group type: COMPARATOR
Intervention: Control (8 g carbohydrate, 0 g protein, 3 g fat)
Number of subjects: 387
Study: 11785111

Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (IORT) combined with preoperative irradiation and radical surgery
Number of subjects: 0
Study: 9212142

Group type: EXPERIMENTAL
Intervention: Isoflurane (0.4‐1.2 vol%)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Propofol (3‐5 mg x kg(‐1) x h(‐1) intravenously)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Both isoflurane and propofol
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Threshold value of Nb
Number of subjects: 40
Study: 7963201

Group type: EXPERIMENTAL
Intervention: Prevention team intervention (flowsheet used, patient education offered, staff tasks redefined)
Number of subjects: 1202

Group type: EXPERIMENTAL
Intervention: Patient education intervention
Number of subjects: 1202

Group type: COMPARATOR
Intervention: Control group (no further intervention)
Number of subjects: 1202

Group type: EXPERIMENTAL
Intervention: Prevention team intervention
Number of subjects: 1202
Study: 3671250

Group type: EXPERIMENTAL
Intervention: nifedipine (up to 60 mg/day)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: prazosin (up to 20 mg/day)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: hydralazine (up to 200 mg/day)
Number of subjects: 93
Study: 30922878

Group type: EXPERIMENTAL
Intervention: ABCP (atezolizumab plus bevacizumab plus carboplatin plus paclitaxel)
Number of subjects: 1202

Group type: COMPARATOR
Intervention: BCP (bevacizumab plus carboplatin plus paclitaxel)
Number of subjects: 1202

Group type: EXPERIMENTAL
Intervention: ABCP
Number of subjects: 1202

Group type: EXPERIMENTAL
Intervention: ACP (atezolizumab plus carboplatin plus paclitaxel)
Number of subjects: 1202

Group type: EXPERIMENTAL
Intervention: ACP
Number of subjects: 1202

Group type: COMPARATOR
Intervention: BCP
Number of subjects: 1202
Study: 30273216

Group type: EXPERIMENTAL
Intervention: Nurse intervention the day before surgery and admission in the ICU
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual care (Control group)
Number of subjects: 40
Study: 26825788

Group type: EXPERIMENTAL
Intervention: XLIF
Number of subjects: 55

Group type: COMPARATOR
Intervention: MIS TLIF
Number of subjects: 55
Study: 24641328

Group type: EXPERIMENTAL
Intervention: -6° head-down bed rest for 60 days
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Hypobaric hypoxia at Concordia station
Number of subjects: 49
Study: 22578243

Group type: EXPERIMENTAL
Intervention: Lactose malabsorption
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Fructose malabsorption
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Open provocation with lactose
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Open provocation with fructose
Number of subjects: 220

Group type: COMPARATOR
Intervention: DBPC provocation with lactose
Number of subjects: 220

Group type: COMPARATOR
Intervention: DBPC provocation with fructose
Number of subjects: 220
Study: 20118387

Group type: EXPERIMENTAL
Intervention: Prescription omega-3-acid ethyl esters plus atorvastatin (10 mg/d)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Prescription omega-3-acid ethyl esters plus atorvastatin (20 mg/d)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Prescription omega-3-acid ethyl esters plus atorvastatin (40 mg/d)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Prescription omega-3-acid ethyl esters plus atorvastatin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo plus atorvastatin
Number of subjects: 100
Study: 18807572

Group type: EXPERIMENTAL
Intervention: Early placement of single-tooth implants (average 10 days after extraction)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Delayed placement of single-tooth implants (3 months after extraction)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Early placement of single-tooth implants
Number of subjects: 45

Group type: COMPARATOR
Intervention: Delayed placement of single-tooth implants
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Both early and delayed placement of single-tooth implants
Number of subjects: 45
Study: 15477398

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 to 80 mg daily
Number of subjects: 27
Study: 11323340

Group type: EXPERIMENTAL
Intervention: 2 microg/kg fentanyl
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control (intranasal saline)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 1 microg/kg fentanyl
Number of subjects: 150
Study: 9150584

Group type: EXPERIMENTAL
Intervention: High need for closure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low need for closure
Number of subjects: 0
Study: 7898092

Group type: EXPERIMENTAL
Intervention: Cilazapril (ACE inhibitor)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 3110316

Group type: EXPERIMENTAL
Intervention: gelatine + Solcoseryl
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: gelatine + Solcoseryl + propyl‐hydroxy‐benzoic‐acid
Number of subjects: 300

Group type: COMPARATOR
Intervention: gelatine
Number of subjects: 300
Study: 29771194

Group type: EXPERIMENTAL
Intervention: +aPL
Number of subjects: 1208

Group type: COMPARATOR
Intervention: -aPL
Number of subjects: 1208

Group type: EXPERIMENTAL
Intervention: +aCL IgM
Number of subjects: 1208

Group type: EXPERIMENTAL
Intervention: two positive aPL
Number of subjects: 1208

Group type: EXPERIMENTAL
Intervention: +a‐β2‐I IgM
Number of subjects: 1208
Study: 26925492

Group type: EXPERIMENTAL
Intervention: Weight loss intervention (8 weeks duration)
Number of subjects: 26
Study: 25514667

Group type: EXPERIMENTAL
Intervention: ICP-targeted treatment
Number of subjects: 105

Group type: COMPARATOR
Intervention: Standard intensive care (control)
Number of subjects: 105
Study: 23290985

Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg q4w
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg q2w or 300 mg q4w or 150 mg q4w
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Secukinumab (all doses)
Number of subjects: 274

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 274
Study: 20610788

Group type: EXPERIMENTAL
Intervention: Strong elliptic velocity profile motor training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weak elliptic velocity profile motor training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group with linear trajectories
Number of subjects: 0
Study: 18206950

Group type: EXPERIMENTAL
Intervention: 20 mg vardenafil daily for 6 months
Number of subjects: 200

Group type: COMPARATOR
Intervention: 100 mg sildenafil daily for 6 months
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 16311189

Group type: EXPERIMENTAL
Intervention: Analogy learning condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Errorless learning condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Discovery learning condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Concurrent verbal task
Number of subjects: 0
Study: 14615726

Group type: EXPERIMENTAL
Intervention: 7.5 mg per day of elemental iron as ferrous sulfate
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 10771453

Group type: EXPERIMENTAL
Intervention: Ziprasidone 80 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 8716423

Group type: EXPERIMENTAL
Intervention: Plaster checks performed by nurses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Plaster checks performed by doctors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Institution of the process allowing nurses to perform plaster checks
Number of subjects: 0
Study: 1571119

Group type: EXPERIMENTAL
Intervention: Ear canal disinfection with 70% alcohol or povidone‐iodine
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Presence of a bacterial pathogen in the ear canal
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Presence of a bacterial pathogen in the middle ear effusion
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Presence of inflamed middle ear mucosa at surgery
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Systemic antimicrobial treatment in children with inflamed middle ear mucosa or positive cultures
Number of subjects: 157